Drug-Coated Balloon-Based Versus Drug-Eluting Stent--Only Treatment in Patients With Chronic Kidney Disease

초록

Chronic kidney disease (CKD) is associated with a high bleeding risk after percutaneous coronary intervention (PCI), but evidence on the efficacy of drug-coated balloon (DCB) treatment in this population remains limited. This study aimed to compare the bleeding risk of DCB-based PCI with that of drug-eluting stent (DES)-only PCI in patients with CKD. We retrospectively enrolled 415 consecutive patients with CKD who underwent DCB-based PCI and propensity score-matched them (1:1) to 415 patients who underwent conventional PCI with second-generation DES (DES-only group). CKD was defined as eGFR <60 mL/min/1.73 m(2). The primary end point was the incidence of major bleeding at 2 years, and the secondary end point was major adverse cardiovascular events (MACE). Baseline characteristics were comparable between the two groups. In the DCB-based group, 65.1% of patients were treated with DCB-only. At 2-year, DCB-based PCI group showed a significantly lower incidence of major bleeding than DES-only group (2.3% vs 5.9%; hazard ratio 0.41; 95% confidence interval 0.19-0.92; p = 0.030), whereas the incidence of MACE was comparable between groups (10.7% vs 13.0%; hazard ratio 0.77; 95% confidence interval 0.50-1.18; p = 0.230). Five cases of target lesion thrombosis occurred in the DES-only group, but none in the DCB-based group. In multivariable analysis, DCB-based PCI was independently associated with a lower risk of 2-year major bleeding. In conclusion, among patients with CKD, DCB-based PCI was associated with a significantly lower risk of major bleeding compared with DES-only PCI, without a significant difference in MACE. These findings suggest that DCB-based PCI may be a viable strategy to reduce bleeding events in patients with CKD. (c) 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

키워드